Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.98 USD
-0.05 (-2.46%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Cardiol Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 46 | 67 | -99,999 | -99,999 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 1 | 1 | 2 | NA | NA |
Total Current Assets | 27 | 47 | 70 | NA | NA |
Net Property & Equipment | 0 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 27 | 48 | 70 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 6 | 7 | 4 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 0 | 0 | 0 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 0 | 5 | NA | NA |
Total Current Liabilities | 6 | 8 | 9 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 6 | 8 | 9 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 110 | 113 | 114 | NA | NA |
Capital Surplus | 14 | 12 | 10 | NA | NA |
Retained Earnings | -106 | -88 | -67 | NA | NA |
Other Equity | 3 | 3 | 3 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 21 | 40 | 61 | NA | NA |
Total Liabilities & Shareholder's Equity | 27 | 48 | 70 | NA | NA |
Total Common Equity | 21 | 40 | 61 | 0 | 0 |
Shares Outstanding | 65.30 | 64.00 | 61.90 | NA | NA |
Book Value Per Share | 0.32 | 0.63 | 0.98 | 0.00 | 0.00 |
Fiscal Year End for Cardiol Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 18 | 21 | 26 | 30 | 33 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 19 | 23 | 27 | 32 | 35 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 19 | 23 | 27 | 32 | 35 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 7 | 6 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 0 | 1 | 1 |
Total Current Liabilities | 8 | 8 | 6 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8 | 8 | 6 | 6 | 6 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 111 | 112 | 110 | 110 | 110 |
Capital Surplus | 16 | 13 | 14 | 14 | 12 |
Retained Earnings | -116 | -113 | -106 | -101 | -96 |
Other Equity | 0 | 3 | 3 | 3 | 3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 11 | 15 | 21 | 26 | 29 |
Total Liabilities & Shareholder's Equity | 19 | 23 | 27 | 32 | 35 |
Total Common Equity | 11 | 15 | 21 | 26 | 29 |
Shares Outstanding | 69.30 | 68.20 | 65.30 | 64.80 | 64.10 |
Book Value Per Share | 0.16 | 0.22 | 0.32 | 0.40 | 0.45 |